Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

12/31/23 2:10:00 PM ET

$LAB

$SLGC

Biotechnology: Laboratory Analytical Instruments

Industrials

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LAB alert in real time by email

Boston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with Standard BioTools Inc. (NASDAQ:LAB).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231231077712/en/

Get the next $LAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LAB
$SLGC

Company	Date	Price Target	Rating	Analyst
Standard BioTools Inc. $LAB	2/27/2025		Overweight → Sector Weight	KeyBanc Capital Markets
Standard BioTools Inc. $LAB	4/16/2024	$3.50	Buy	TD Cowen
Standard BioTools Inc. $LAB	4/4/2024	$3.25	Buy	Jefferies
SomaLogic Inc. $SLGC	10/5/2023	$3.50 → $2.29	Buy → Hold	Jefferies
SomaLogic Inc. $SLGC	9/25/2023	$5.00 → $2.50	Buy → Hold	Canaccord Genuity
Standard BioTools Inc. $LAB	7/12/2023	$4.00	Overweight	KeyBanc Capital Markets
SomaLogic Inc. $SLGC	2/1/2022	$12.00	Buy	Stifel
SomaLogic Inc. $SLGC	12/14/2021	$19.00	Buy	Canaccord Genuity

More analyst ratings

$LAB
$SLGC
Financials

Live finance-specific insights

Standard BioTools Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a
5/6/25 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor R
4/22/25 7:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies over 12 monthsStrong Balance sheet with $295 million in cash, cash equivalents, restricted cash, short-term investments and no material debt at year end 2024 expected to provide suffi
2/26/25 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials

$LAB
$SLGC
Press Releases

Fastest customizable press release news feed in the world

Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare. The first session will be: Is More Really More? Evaluating the Case for High-Plex, High-Quality ProteomicsFriday, June 6, 2025 – 11:00 am ET Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools wi
5/30/25 7:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Reports First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a
5/6/25 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of new and enhanced proteomic product offerings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. These advancements – including the SomaScan™ Select 3.7K Assay, Single SOMAmer™ Reagents and the next-generation CyTOF™ XT PRO system
4/24/25 7:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials

$LAB
$SLGC
Leadership Updates

Live Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan
11/7/24 8:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
12/12/23 5:31:00 PM ET
$EXAS
$ILMN
$LAB
$ME
Medical Specialities
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
SomaLogic Announces Chief Financial Officer Transition
Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti
6/6/23 4:05:00 PM ET
$SLGC
Biotechnology: Commercial Physical & Biological Resarch
Health Care

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Chat with this insight

Recent Analyst Ratings for $LAB$SLGC

$LAB$SLGC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Standard BioTools downgraded by KeyBanc Capital Markets

TD Cowen initiated coverage on Standard BioTools with a new price target

Jefferies initiated coverage on Standard BioTools with a new price target

$LAB$SLGC Financials

Live finance-specific insights

Standard BioTools Reports First Quarter 2025 Financial Results

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

$LAB$SLGC Press Releases

Fastest customizable press release news feed in the world

Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

Standard BioTools Reports First Quarter 2025 Financial Results

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

$LAB$SLGC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Casdin Partners Master Fund, L.P. disposed of $580,425 worth of shares (545,000 units at $1.06), was granted 58,215 shares, bought $5,134,321 worth of shares (4,820,959 units at $1.06) and acquired $580,425 worth of shares (545,000 units at $1.06) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

$LAB$SLGC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 23,919 shares, decreasing direct ownership by 3% to 819,157 units (SEC Form 4)

President & CEO Egholm Michael covered exercise/tax liability with 9,906 shares, decreasing direct ownership by 0.36% to 2,731,285 units (SEC Form 4)

Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 2,583 shares, decreasing direct ownership by 0.28% to 927,703 units (SEC Form 4)

$LAB$SLGC Leadership Updates

Live Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

$LAB$SLGC SEC Filings

SEC Form SD filed by Standard BioTools Inc.

SEC Form 144 filed by Standard BioTools Inc.

SEC Form 10-Q filed by Standard BioTools Inc.

$LAB$SLGC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
Analyst Ratings

$LAB
$SLGC
Financials

$LAB
$SLGC
Press Releases

$LAB
$SLGC
Insider Purchases

$LAB
$SLGC
Insider Trading

$LAB
$SLGC
Leadership Updates

$LAB
$SLGC
SEC Filings

$LAB
$SLGC
Large Ownership Changes